Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T18:04:54.188Z.
Calculation as of: 2026-10-06T18:04:54.188Z.
Quote observation: 2026-10-06T18:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4aebd5d53392a49c55eaf762d12be1f1a7ff494d091d9ceadcd34fda62bcd254
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$88.34M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$88.21M
Price/OCF Ratio
14.97
TTM Avg
23.76
3Y Avg
35.04
5Y Avg
61.62
Market Cap
$85.91M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | $89.33M | N/A | N/A | N/A | N/A |
| electroCore, Inc. (ECOR)vs › | $89.53M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $89.45M | 3.35 | 4.27 | 2.78 | 3.26 |
| Equillium, Inc. (EQ)vs › | $90.41M | N/A | 24.67 | 24.67 | 24.67 |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $88.34M | N/A | N/A | N/A | N/A |
| Rallybio Corporation (RLYB)vs › | $90.85M | 3.45 | 3.71 | 3.71 | 3.71 |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 14.97 | 23.76 | 35.04 | 61.62 |
| Biomea Fusion, Inc. (BMEA)vs › | $91.46M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $85.91M | N/A | N/A | N/A | N/A |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $92.33M | 0.01 | 1.89 | 1.89 | 1.89 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
